Understand the source comparison
Peptides Andrew Huberman Recommends: Research Compound Comparison
BPC-157 VEGF upregulation, NO pathway modulation 250–500 mcg daily Subcutaneous Accelerated tissue repair in rodent models; human data limited Promising preclinical profile; clinical translation uncertain MK-677 Ghrelin receptor agonism → pulsatile GH release
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, NO pathway modulation
- 250–500 mcg daily
- Subcutaneous
- Accelerated tissue repair in rodent models; human data limited
- Promising preclinical profile; clinical translation uncertain
- MK-677
- Ghrelin receptor agonism → pulsatile GH release
- 10–25 mg daily
- Oral
- Elevates IGF-1 40–90% without GH suppression
- Orally bioavailable GH secretagogue; glucose and appetite increase notable
- CJC-1295/Ipamorelin
- GHRH analog + GHS-R1a agonist
- 100 mcg each before bed
- Dual-pathway GH stimulation without cortisol spike
- Synergistic pulse amplification; does not replicate full exogenous GH
- Cerebrolysin
- Neurotrophic factor mixture (BDNF, NGF analogs)
- 10–30 mL per session IV
- Intravenous
- CREB activation and synaptic plasticity in dementia models
- Clinical data in Eastern Europe; sourcing variability a concern
- Dihexa
- HGF receptor agonism → c-Met signaling
- 1–5 mg/kg (rodent equivalent)
- Oral (research)
- 7× synaptogenesis potency vs BDNF in vitro
- High mechanistic promise; zero human trial data
- Thymosin Beta-4
- Actin sequestration, MMP upregulation
- 6–12 mg weekly
- Cardiac tissue repair and wound remodeling in animal models
- Strong preclinical wound healing data; human trials ongoing